Literature DB >> 20302432

Travel and implications for the elimination of trachoma in ethiopia.

Neelima A Shah1, Jenafir House, Takele Lakew, Wondu Alemayehu, Colleen Halfpenny, Kevin C Hong, Jeremy D Keenan, Travis C Porco, John P Whitcher, Thomas M Lietman, Bruce D Gaynor.   

Abstract

PURPOSE: Trachoma is the leading infectious cause of blindness. The World Health Organization has set a goal of reducing the trachoma disease burden to a level where it is no longer a public health concern by the year 2020. Some investigators feel that local elimination of ocular chlamydia infection is possible, but little has been done to study the likelihood of reintroduction of infection from neighboring areas. Mass administration of azithromycin has been shown to dramatically reduce the prevalence of infection in many villages in central Ethiopia. However, after treatment is discontinued, infection returns. Reintroduction of infection could occur from the few remaining infected cases in a treated community or from outside the community. People traveling between villages might be responsible thus complicating the elimination of trachoma.
METHODS: We conducted a survey to assess the travel pattern of the Gurage zone residents in Ethiopia. Seven hundred and seventeen households with at least one child aged 1-5 years in 48 villages were surveyed to collect the details of travel in 1 month prior to the survey.
RESULTS: Seventy-eight percent of the surveyed households had at least one traveler, with the majority being women. Pre-school children, the main reservoir of clinically active infection, rarely traveled. Most travel was to the market or to school, and most for less than 1 day.
CONCLUSIONS: Travel routinely takes place in these villages. Trachoma control programs in this area might consider treating areas with the same markets and schools in the same period to increase the efficacy of mass treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20302432     DOI: 10.3109/09286581003624921

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  12 in total

1.  Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.

Authors:  Sheila K West; Beatriz E Munoz; Harran Mkocha; Charlotte Gaydos; Thomas Quinn
Journal:  Ophthalmic Epidemiol       Date:  2015       Impact factor: 1.648

Review 2.  Chlamydial infection during trachoma monitoring: are the most difficult-to-reach children more likely to be infected?

Authors:  Jeremy D Keenan; J Moncada; T Gebre; B Ayele; M C Chen; S N Yu; P M Emerson; N E Stoller; C E McCulloch; B D Gaynor; J Schachter
Journal:  Trop Med Int Health       Date:  2011-11-28       Impact factor: 2.622

3.  Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.

Authors:  Ann-Margret Ervin; Harran Mkocha; Beatriz Munoz; Kurt Dreger; Laura Dize; Charlotte Gaydos; Thomas C Quinn; Sheila K West
Journal:  Ophthalmic Epidemiol       Date:  2016-11-07       Impact factor: 1.648

4.  Follicular trachoma and trichiasis prevalence in an urban community in The Gambia, West Africa: is there a need to include urban areas in national trachoma surveillance?

Authors:  E Quicke; A Sillah; E M Harding-Esch; A Last; H Joof; P Makalo; R L Bailey; S E Burr
Journal:  Trop Med Int Health       Date:  2013-09-06       Impact factor: 2.622

5.  Risk factors for ocular chlamydia after three mass azithromycin distributions.

Authors:  Berhan Ayele; Teshome Gebre; Jeanne Moncada; Jenafir I House; Nicole E Stoller; Zhaoxia Zhou; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2011-12-13

6.  Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Laura Dize; Charlotte A Gaydos; Bonnie Swenor; Ann-Margret Ervin; Thomas C Quinn
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

7.  Trachoma prevalence remains below threshold in five districts after stopping mass drug administration: results of five surveillance surveys within a hyperendemic setting in Amhara, Ethiopia.

Authors:  Scott D Nash; Aisha E P Stewart; Tigist Astale; Eshetu Sata; Mulat Zerihun; Demelash Gessese; Berhanu Melak; Gedefaw Ayenew; Zebene Ayele; Belay Bayissasse; Melsew Chanyalew; Zerihun Tadesse; E Kelly Callahan
Journal:  Trans R Soc Trop Med Hyg       Date:  2018-12-01       Impact factor: 2.184

8.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

9.  Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors.

Authors:  Tansy Edwards; Elizabeth Allen; Emma M Harding-Esch; John Hart; Sarah E Burr; Martin J Holland; Ansumana Sillah; Sheila K West; David Mabey; Robin Bailey
Journal:  PLoS Negl Trop Dis       Date:  2014-08-28

10.  Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia.

Authors:  Tigist Astale; Eshetu Sata; Mulat Zerihun; Andrew W Nute; Aisha E P Stewart; Demelash Gessese; Gedefaw Ayenew; Berhanu Melak; Melsew Chanyalew; Zerihun Tadesse; E Kelly Callahan; Scott D Nash
Journal:  PLoS Negl Trop Dis       Date:  2018-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.